Sanofi-aventis

Sanofi-aventis

Sanofi-aventis is a drugs company from Malvern, Pennsylvania

History from 1973-1999

Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales. Originally, the company was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo.

History from 1999-till date

In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.

Sanofi_Pasteur

Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines. Sanofi Pasteur is one of four global producers of the yellow fever vaccine.

Sanofi–GSK COVID-19 vaccine

The Sanofi–GSK COVID-19 vaccine code-named VAT00002 and VAT00008 (with adjuvant) is a COVID-19 vaccine candidate developed by Sanofi Pasteur and GSK.

Investigational therapies

• Amcenestrant is an oral selective estrogen receptor degrader, which aims to be the new standard of care in hormone-receptor-positive breast cancer;
• Fitusiran is a small interference RNA therapeutic in development for the treatment of hemophilia A and B with or without inhibitors, with the potential to be a first-in-class therapeutic option;
• Efanesoctocog alfa is a new class of factor therapy engineered to achieve higher factor levels with the potential to deliver unprecedented protection for people with hemophilia A, allowing them to achieve near-normal factor activity with a once-weekly dose;
• Amlitelimab a non-depleting aOX40Ligand monocloncal antibody has the potential to bebest-in-class treatment for a range of immune-mediated diseases and inflammatory disorders, including moderate-to-severe atopic dermatitis. By targeting OX40-Ligand, amlitelimab aims to restore immune homeostasis between pro-inflammatory and anti-inflammatory T cells;
• Nirsevimab, a monoclonal antibody, is a potentially cost-effective prevention against respiratory syncytial virus (RSV), for all infants. Its high affinity to RSV could potentially allow a single injection to cover for the entire RSV season;
• Tolebrutinib is an oral selective, brain penetrant BTK inhibitor with the potential to be the first disease-modifier to address sources of multiple sclerosis damage in the brain.

Oncology and immunology products

Sanofi-Aventis has a strong focus on oncology and immunology as noted they below as of 2022.

• i.Sanofi-Aventis has entered into a licensing agreement with Biond Biologics with respect to BND-22, a novel immune checkpoint inhibitor targeting the ILT2 receptor;
• ii.Sanofi-Aventis has signed an exclusive worldwide licensing agreement with C4X with respect to the C4XD oral IL-17A inhibitor program;
• iii.Sanofi-Aventis has entered into a new license agreement with Eureka Therapeutics, Inc. on GPRC5D, targeting multiple myeloma;
• iv.Sanofi-Aventis has committed to invest in equity in Gyroscope Therapeutics Holdings plc to further validate the potential of the GT005 investigational gene therapy in geographic atrophy and support the ongoing Phase II development program;
• v.Sanofi-Aventis has invested $180 million of equity in Owkin’s artificial intelligence and federated learning to advance our oncology pipeline;
• vi.Sanofi-Aventis has established a strategic research collaboration and license agreement with Exscientia to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilizing actual patient samples;
• vii.Sanofi-Aventis has acquired Kymab Group Ltd.;
• viii.Sanofi-Aventis has acquired Kiadis Pharma N.V.;
• ix.Sanofi-Aventis has acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells;
• x.Sanofi-Aventis has completed the acquisition of Translate Bio, further accelerating our efforts to develop transformative vaccines and therapies using mRNA technology;
• xi.Sanofi-Aventis has acquired Origimm Biotechnology GmbH, a company with an innovative program to treat acne with vaccine-based immunotherapy; and
• xii.Sanofi-Aventis has entered into an agreement to acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company leveraging its proprietary, clinically validated XTEN® and innovative universal protease-releasable masking technology platform, Pro-XTENTM, to discover and develop transformative T-cell engagers (TCE) and cytokine therapies for patients with cancer.